Meeting
2018 Genitourinary Cancers Symposium
Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).
Authors
Phillip Lee Palmbos
University of Michigain Health System, Ann Arbor, MI
Phillip Lee Palmbos , Scott A. Tomlins , Neeraj Agarwal , Przemyslaw Twardowski , Alicia K. Morgans , William Kevin Kelly , Vivek Arora , Emmanuel S. Antonarakis , Javed Siddiqui , Stephanie Daignault , Karen E. Knudsen , Felix Y Feng , Maha Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02059213
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 251)
DOI
10.1200/JCO.2018.36.6_suppl.251
Abstract #
251
Poster Bd #
M5
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Phillip Lee Palmbos
Poster
2015 ASCO Annual Meeting
A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.
First Author: Phillip Lee Palmbos
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Phillip Lee Palmbos
Poster
2014 ASCO Annual Meeting
Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.
First Author: Erica L. Mayer